Beyond Air, Inc. (NASDAQ:XAIR) Expected to Post Earnings of -$0.24 Per Share

Wall Street analysts expect that Beyond Air, Inc. (NASDAQ:XAIRGet Rating) will post earnings per share of ($0.24) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Beyond Air’s earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.27). Beyond Air also posted earnings per share of ($0.24) in the same quarter last year. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Beyond Air will report full-year earnings of ($1.18) per share for the current fiscal year, with EPS estimates ranging from ($1.22) to ($1.15). For the next financial year, analysts expect that the firm will report earnings of ($0.84) per share, with EPS estimates ranging from ($1.00) to ($0.57). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Beyond Air.

Beyond Air (NASDAQ:XAIRGet Rating) last released its earnings results on Thursday, February 10th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.04). During the same period in the previous year, the firm earned ($0.33) EPS.

Separately, Zacks Investment Research downgraded shares of Beyond Air from a “buy” rating to a “hold” rating in a report on Thursday, April 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $13.70.

In other Beyond Air news, Director Robert Carey purchased 20,000 shares of Beyond Air stock in a transaction that occurred on Tuesday, April 5th. The shares were bought at an average price of $6.71 per share, for a total transaction of $134,200.00. Following the completion of the transaction, the director now owns 567,323 shares of the company’s stock, valued at approximately $3,806,737.33. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 43,685 shares of company stock worth $293,447 in the last 90 days. 11.90% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its position in Beyond Air by 6.8% during the first quarter. BlackRock Inc. now owns 264,900 shares of the company’s stock valued at $1,769,000 after acquiring an additional 16,968 shares during the last quarter. Meitav Dash Investments Ltd. increased its position in Beyond Air by 96.0% during the first quarter. Meitav Dash Investments Ltd. now owns 26,542 shares of the company’s stock valued at $179,000 after acquiring an additional 13,000 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Beyond Air during the first quarter valued at $208,000. Baldwin Brothers LLC MA increased its position in Beyond Air by 12.3% during the first quarter. Baldwin Brothers LLC MA now owns 45,500 shares of the company’s stock valued at $304,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Resources Investment Advisors LLC. bought a new position in Beyond Air during the fourth quarter valued at $116,000. Institutional investors and hedge funds own 21.05% of the company’s stock.

Shares of XAIR stock traded up $0.10 during mid-day trading on Thursday, hitting $5.06. The company had a trading volume of 283,949 shares, compared to its average volume of 247,958. Beyond Air has a 52-week low of $4.62 and a 52-week high of $16.41. The stock’s 50 day moving average price is $6.59 and its 200-day moving average price is $8.54. The company has a market capitalization of $150.94 million, a P/E ratio of -4.13 and a beta of -0.40.

Beyond Air Company Profile (Get Rating)

Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors.

Recommended Stories

Get a free copy of the Zacks research report on Beyond Air (XAIR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Beyond Air (NASDAQ:XAIR)

Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.